Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab.
about
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesLymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disordersEpstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplantEpstein-Barr Virus-associated Lymphoproliferative Disorder with Encephalitis Following Anti-thymocyte Globulin for Aplastic Anemia Resolved with Rituximab Therapy: A Case Report and Literature ReviewPost-transplant lymphoproliferative disorder of the adrenal gland after allogeneic hematopoietic stem cell transplantation: report of two cases and literature review.A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders.Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.The impact of targeting repetitive BamHI-W sequences on the sensitivity and precision of EBV DNA quantification.Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders.Comprehensive review of post-organ transplant hematologic cancers.
P2860
Q26745838-5711473F-8196-426A-AEAE-37399F2610B0Q26776151-8F9E1CB5-CEFC-4D51-A77B-2E95799D1467Q26861623-C23A5D63-989B-42E5-AD27-4BE3310CDA71Q33619215-A403EE7B-AAAE-477B-8026-8E8599BA1CCEQ38596739-8ADA8011-02A6-411B-8D44-A47FD7FDED1BQ38619244-3FE446C6-189B-45BF-AFCB-4985F1675C41Q39978862-A18181D7-9EE4-4A7D-BB0B-7CBCC8CCC025Q40066662-113D943D-610F-4BAC-8DED-5962563203DBQ41549338-D3ABED8A-DE99-4A30-8957-0113E8DDB2B2Q42660665-DCB67B7B-8443-433F-9A08-0D16F1DF82F4Q47572480-B450CAFD-FC31-4FD9-9D17-1588B1D8ECC1
P2860
Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Reduced PTLD-related mortality ...... orating pre-emptive rituximab.
@en
Reduced PTLD-related mortality ...... orating pre-emptive rituximab.
@nl
type
label
Reduced PTLD-related mortality ...... orating pre-emptive rituximab.
@en
Reduced PTLD-related mortality ...... orating pre-emptive rituximab.
@nl
prefLabel
Reduced PTLD-related mortality ...... orating pre-emptive rituximab.
@en
Reduced PTLD-related mortality ...... orating pre-emptive rituximab.
@nl
P2093
P2860
P356
P1476
Reduced PTLD-related mortality ...... orating pre-emptive rituximab.
@en
P2093
A F J de Haan
F F Stelma
J P Donnelly
N M A Blijlevens
W B C Stevens
W J F M van der Velden
P2860
P2888
P304
P356
10.1038/BMT.2013.84
P407
P577
2013-06-10T00:00:00Z
P5875
P6179
1044466982